Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 ASCEND-5: too little too late?

Literature DB >> 29268320

ASCEND-5: too little too late?

Fengying Wu¹, Sai-Hong Ignatius Ou².

Abstract

Year: 2017 PMID： 29268320 PMCID： PMC5723760 DOI： 10.21037/jtd.2017.08.147

Source DB: PubMed Journal: J Thorac Dis ISSN： 2072-1439 Impact factor: 2.895

× No keyword cloud information.

15 in total

1. Progression-Free and Overall Survival in ALK-Positive NSCLC Patients Treated with Sequential Crizotinib and Ceritinib.

Authors: Justin F Gainor; Daniel S W Tan; Tomasso De Pas; Benjamin J Solomon; Aziah Ahmad; Chiara Lazzari; Filippo de Marinis; Gianluca Spitaleri; Katherine Schultz; Luc Friboulet; Beow Y Yeap; Jeffrey A Engelman; Alice T Shaw
Journal: Clin Cancer Res Date: 2015-02-27 Impact factor: 12.531

2. Further Advances in the Management of Anaplastic Lymphoma Kinase-Mutated Non-Small-Cell Lung Cancer.

Authors: Sai-Hong Ignatius Ou
Journal: J Clin Oncol Date: 2017-05-11 Impact factor: 44.544

3. FDA approval: ceritinib for the treatment of metastatic anaplastic lymphoma kinase-positive non-small cell lung cancer.

Authors: Sean Khozin; Gideon M Blumenthal; Lijun Zhang; Shenghui Tang; Margaret Brower; Emily Fox; Whitney Helms; Ruby Leong; Pengfei Song; Yuzhuo Pan; Qi Liu; Ping Zhao; Hong Zhao; Donghao Lu; Zhe Tang; Ali Al Hakim; Karen Boyd; Patricia Keegan; Robert Justice; Richard Pazdur
Journal: Clin Cancer Res Date: 2015-03-09 Impact factor: 12.531

4. The ALK inhibitor ceritinib overcomes crizotinib resistance in non-small cell lung cancer.

Authors: Luc Friboulet; Nanxin Li; Ryohei Katayama; Christian C Lee; Justin F Gainor; Adam S Crystal; Pierre-Yves Michellys; Mark M Awad; Noriko Yanagitani; Sungjoon Kim; AnneMarie C Pferdekamper; Jie Li; Shailaja Kasibhatla; Frank Sun; Xiuying Sun; Su Hua; Peter McNamara; Sidra Mahmood; Elizabeth L Lockerman; Naoya Fujita; Makoto Nishio; Jennifer L Harris; Alice T Shaw; Jeffrey A Engelman
Journal: Cancer Discov Date: 2014-03-27 Impact factor: 39.397

5. Synthesis, structure-activity relationships, and in vivo efficacy of the novel potent and selective anaplastic lymphoma kinase (ALK) inhibitor 5-chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-(2-(isopropylsulfonyl)phenyl)pyrimidine-2,4-diamine (LDK378) currently in phase 1 and phase 2 clinical trials.

Authors: Thomas H Marsilje; Wei Pei; Bei Chen; Wenshuo Lu; Tetsuo Uno; Yunho Jin; Tao Jiang; Sungjoon Kim; Nanxin Li; Markus Warmuth; Yelena Sarkisova; Frank Sun; Auzon Steffy; AnneMarie C Pferdekamper; Allen G Li; Sean B Joseph; Young Kim; Bo Liu; Tove Tuntland; Xiaoming Cui; Nathanael S Gray; Ruo Steensma; Yongqin Wan; Jiqing Jiang; Greg Chopiuk; Jie Li; W Perry Gordon; Wendy Richmond; Kevin Johnson; Jonathan Chang; Todd Groessl; You-Qun He; Andrew Phimister; Alex Aycinena; Christian C Lee; Badry Bursulaya; Donald S Karanewsky; H Martin Seidel; Jennifer L Harris; Pierre-Yves Michellys
Journal: J Med Chem Date: 2013-06-26 Impact factor: 7.446

6. Alectinib versus Crizotinib in Untreated ALK-Positive Non-Small-Cell Lung Cancer.

Authors: Solange Peters; D Ross Camidge; Alice T Shaw; Shirish Gadgeel; Jin S Ahn; Dong-Wan Kim; Sai-Hong I Ou; Maurice Pérol; Rafal Dziadziuszko; Rafael Rosell; Ali Zeaiter; Emmanuel Mitry; Sophie Golding; Bogdana Balas; Johannes Noe; Peter N Morcos; Tony Mok
Journal: N Engl J Med Date: 2017-06-06 Impact factor: 91.245

7. Ceritinib versus chemotherapy in patients with ALK-rearranged non-small-cell lung cancer previously given chemotherapy and crizotinib (ASCEND-5): a randomised, controlled, open-label, phase 3 trial.

Authors: Alice T Shaw; Tae Min Kim; Lucio Crinò; Cesare Gridelli; Katsuyuki Kiura; Geoffrey Liu; Silvia Novello; Alessandra Bearz; Oliver Gautschi; Tony Mok; Makoto Nishio; Giorgio Scagliotti; David R Spigel; Stéphanie Deudon; Cheng Zheng; Serafino Pantano; Patrick Urban; Cristian Massacesi; Kalyanee Viraswami-Appanna; Enriqueta Felip
Journal: Lancet Oncol Date: 2017-06-09 Impact factor: 41.316

8. First-line crizotinib versus chemotherapy in ALK-positive lung cancer.

Authors: Benjamin J Solomon; Tony Mok; Dong-Wan Kim; Yi-Long Wu; Kazuhiko Nakagawa; Tarek Mekhail; Enriqueta Felip; Federico Cappuzzo; Jolanda Paolini; Tiziana Usari; Shrividya Iyer; Arlene Reisman; Keith D Wilner; Jennifer Tursi; Fiona Blackhall
Journal: N Engl J Med Date: 2014-12-04 Impact factor: 91.245

9. ASCEND-8: A Randomized Phase 1 Study of Ceritinib, 450 mg or 600 mg, Taken with a Low-Fat Meal versus 750 mg in Fasted State in Patients with Anaplastic Lymphoma Kinase (ALK)-Rearranged Metastatic Non-Small Cell Lung Cancer (NSCLC).

Authors: Byoung Chul Cho; Dong-Wan Kim; Alessandra Bearz; Scott A Laurie; Mark McKeage; Gloria Borra; Keunchil Park; Sang-We Kim; Marwan Ghosn; Andrea Ardizzoni; Evaristo Maiello; Alastair Greystoke; Richard Yu; Karen Osborne; Wen Gu; Jeffrey W Scott; Vanessa Q Passos; Yvonne Y Lau; Anna Wrona
Journal: J Thorac Oncol Date: 2017-07-17 Impact factor: 15.609

10. Activity and safety of ceritinib in patients with ALK-rearranged non-small-cell lung cancer (ASCEND-1): updated results from the multicentre, open-label, phase 1 trial.

Authors: Dong-Wan Kim; Ranee Mehra; Daniel S W Tan; Enriqueta Felip; Laura Q M Chow; D Ross Camidge; Johan Vansteenkiste; Sunil Sharma; Tommaso De Pas; Gregory J Riely; Benjamin J Solomon; Jürgen Wolf; Michael Thomas; Martin Schuler; Geoffrey Liu; Armando Santoro; Santosh Sutradhar; Siyu Li; Tomasz Szczudlo; Alejandro Yovine; Alice T Shaw
Journal: Lancet Oncol Date: 2016-03-11 Impact factor: 41.316

1 in total

Review 1. Anaplastic lymphoma kinase tyrosine kinase inhibitors in non-small cell lung cancer.

Authors: Tiziana Vavalà; Annapaola Mariniello; Silvia Novello
Journal: Transl Cancer Res Date: 2019-01 Impact factor: 1.241

1 in total